Genentech (Horizon)

Who is the sponsor?
Genentech

Who are the patients?
Patients who have completed participation in certain other LucentisTM clinical studies and meet the eligibility criteria.

How long are the eligible patients enrollment?
3 years

When did participation agreement start at our site?
2005

What is the enrollment goal for the sponsor?
Not stated

Is the enrollment still open?
No. This study is now closed.

What is this study investigating?
Phase III open-label extension study, which allows eligible patients who have completed participation in certain other LucentisTM clinical studies to continue to receive the investigational drug.

How is the treatment administered?
Intravitreal injections.